Clinical Insights

Clinical Insights: July 6, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Qsymia® (phentermine and topiramate) Extended-Release Capsules – New Label Expansion – June 24, 2022 – The U.S. Food and Drug Administration has approved…

Read More...

Clinical Insights: June 29, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Breyanzi® (lisocabtagene maraleucel) – New Label Expansion – June 24, 2022 – The Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi®, Juno Therapeutics,…

Read More...

Clinical Insights: June 22, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Imcivree® (setmelanotide) Injection – New Approved Indication – June 16, 2022 – Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company committed to transforming the…

Read More...

Clinical Insights: June 15, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Amvuttra™ (vutrisiran) – New Drug Approval – June 13, 2022 – Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration (FDA) approved…

Read More...

Clinical Insights: June 8, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval No new update. New Indication/Dosage/Formulation Approval No new update. New Drug Shortage June 03, 2022 Nystatin Ointment (Discontinuation) Updated Drug Shortage June 06, 2022 Iodixanol (Visipaque) Injection (Currently in…

Read More...

Clinical Insights: June 2, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Vtama® (tapinarof) Cream – New Drug Approval – May 24, 2022 – Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, announced that the…

Read More...

Clinical Insights: May 25, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Vidaza® (azacytidine) Injection – New Drug Approval – May 20, 2022 – The Food and Drug Administration approved azacitidine (Vidaza®, Celgene Corp.) for pediatric patients with newly diagnosed juvenile…

Read More...

Clinical Insights: May 18, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Mounjaro™ (tirzepatide) Injection – New Drug Approval – May 13, 2022 – The U.S. Food and Drug Administration approved Mounjaro™ (tirzepatide) injection to improve blood sugar control in adults…

Read More...

Clinical Insights: May 11, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Voquezna™ Dual Pak™ (amoxicillin and vonoprazan) Voquezna™ Triple Pak™ (vonoprazan, amoxicillin, clarithromycin) Co-Packaged – New Drug Approval – May 3, 2022 – Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused…

Read More...

Clinical Insights: May 4, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Cuvrior™ (trientine tetrahydrochloride) Tablets – New Drug Approval – May 2, 2022 – Orphalan SA, an international orphan drug development and commercialisation company, announces approval of Cuvrior™, a new…

Read More...

Clinical Insights: April 27, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval No new update. New Indication/Dosage/Formulation Approval Veklury® (remdesivir) Injection – New Expanded Indication – April 25, 2022 – Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration…

Read More...

Clinical Insights: April 20, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval No new update. New Indication/Dosage/Formulation Approval No new update. New/Updated Drug Shortage April 18, 2022 Chlordiazepoxide Hydrochloride Capsules (Currently in Shortage) Digoxin Injection (Currently in Shortage) Disopyramide Phosphate (Norpace)…

Read More...